Contract service providers share insights on biopharma market developments and the implications of biosimilar drug approvals.
The approval of the first biosimilar in the United States, as well as continuing consolidation in the biopharma and contract development and manufacturing markets, are just two indicators of the ongoing evolution of biopharmaceutical development. Representatives of contract service providers shared observations, trends and projections with BioPharm International.
Download
BioPharm International’s 2015 Outsourcing Resources eBook.
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.